Watson has made available Generess Fe (norethindrone and ethinyl estradiol chewable tablets and ferrous fumarate chewable tablets), a low-dose oral contraceptive for the prevention of pregnancy. Generess Fe was approved based on data from a multicenter, noncomparative, open-label study with a treatment duration of 12 months. In 1,677 women aged 18–46, Generess Fe was proved effective in preventing pregnancy, with a Pearl Index of 2.01 pregnancies per 100 women-years of treatment.
Generess Fe is a once-daily, 28-day regimen providing 24 tablets of norethindrone 0.8mg and ethinyl estradiol 25mcg plus four tablets of ferrous fumarate 75mg.
For more information call (800) 272-5525 or visit www.generess.com.